Although the underlying mechanisms of pulmonary vascular remodeling in PAH are not completely understood, therapies targeting reduced prostacyclin synthesis, increased endothelin signaling and increased cyclic nucleotide phosphodiesterase (PDE) levels have been approved for the treatment of PAH [3]–[5]. This evidence concerns the gene ALDH7A1 and pulmonary arterial hypertension.